Merit Medical Systems (MMSI) Hisse Özeti
Merit Medical Systems, Inc. girişimsel, tanısal ve terapötik prosedürler için tek kullanımlık tıbbi ürünler tasarlar, geliştirir, üretir ve Amerika Birleşik Devletleri, Çin, Japonya, Almanya, Fransa, Birleşik Krallık ve uluslararası alanda pazarlar. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
MMSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merit Medical Systems, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$90.76 |
| 52 Haftanın En Yüksek Seviyesi | US$94.75 |
| 52 Haftanın En Düşük Seviyesi | US$59.74 |
| Beta | 0.48 |
| 1 Aylık Değişim | 22.67% |
| 3 Aylık Değişim | 42.32% |
| 1 Yıllık Değişim | 5.34% |
| 3 Yıllık Değişim | 33.86% |
| 5 Yıllık Değişim | 29.32% |
| Halka arzdan bu yana değişim | 1,650.72% |
Son Haberler & Güncellemeler
MMSI: Raised 2026 Outlook And Rich P/E Suggest Fairly Balanced Setup
Analysts have lifted the Merit Medical Systems fair value estimate from $89.55 to $100.27, pointing to higher price targets across the Street, supported by views of solid growth, improving margins and a slightly lower discount rate, even as some see the current P/E multiple as leaving limited room for further upside. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of optimism around execution and growth, alongside some caution on valuation and future upside.
MMSI: Strong Q2 Execution And 2026 Guidance Will Test Earnings Power
Merit Medical Systems' analyst fair value estimate has increased from $74.00 to $83.00, in line with higher Street price targets after analysts highlighted a strong Q2 report, a rebound in organic growth, raised 2026 guidance and expectations for improved margins and earnings power. Analyst Commentary The recent research coverage on Merit Medical Systems centers on a stronger Q2 print, higher 2026 guidance and a series of upward price target revisions.Recent updates
MMSI: Raised 2026 Outlook And Rich P/E Suggest Fairly Balanced Setup
Analysts have lifted the Merit Medical Systems fair value estimate from $89.55 to $100.27, pointing to higher price targets across the Street, supported by views of solid growth, improving margins and a slightly lower discount rate, even as some see the current P/E multiple as leaving limited room for further upside. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of optimism around execution and growth, alongside some caution on valuation and future upside.MMSI: Strong Q2 Execution And 2026 Guidance Will Test Earnings Power
Merit Medical Systems' analyst fair value estimate has increased from $74.00 to $83.00, in line with higher Street price targets after analysts highlighted a strong Q2 report, a rebound in organic growth, raised 2026 guidance and expectations for improved margins and earnings power. Analyst Commentary The recent research coverage on Merit Medical Systems centers on a stronger Q2 print, higher 2026 guidance and a series of upward price target revisions.
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
Summary Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026. Despite softer organic growth and CEO transition, Merit's business remains resilient, with potential for re-rating as growth drivers materialize. Read the full article on Seeking AlphaTariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside
Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential
Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Merit Medical: A Success Story That Keeps Getting Better
Summary Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical’s lead management portfolio, enhance Merit’s product portfolio and offer longer-term synergies. CEO succession remains a concern, but could also prompt a bid for the company. Despite not being "super cheap", Merit’s strong execution, revenue growth, and margin leverage justify a positive rating, with potential for further valuation uplift. Read the full article on Seeking AlphaMerit Medical Systems: Solid Execution, Stretched Valuations
Summary Merit Medical Systems' stock is up 40% from last spring's lows, driven by strong Q3 results and positive analyst sentiment. The stock's rally has stalled recently. The company has also made a small acquisition in September and garnered a key FDA approval to close out 2024 on a high note. More upside ahead, or will the shares experience further profit-taking? An analysis of Merit Medical Systems follows in the paragraphs below. Read the full article on Seeking AlphaHissedar Getirileri
| MMSI | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 1.1% | 2.7% | 0.6% |
| 1Y | 5.3% | -11.6% | 20.1% |
Getiri vs. Endüstri: MMSI geçen yıl % -11.6 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: MMSI geçen yıl % 20.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| MMSI volatility | |
|---|---|
| MMSI Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: MMSI son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: MMSI 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1987 | 7,500 | Martha Aronson | www.merit.com |
Merit Medical Systems, Inc. girişimsel, tanısal ve terapötik prosedürler için tek kullanımlık tıbbi ürünler tasarlar, geliştirir, üretir ve Amerika Birleşik Devletleri, Çin, Japonya, Almanya, Fransa, Birleşik Krallık ve uluslararası alanda pazarlar. Kardiyovasküler ve Endoskopi olmak üzere iki segmentte faaliyet göstermektedir. Şirket, mikropunktur kitleri, anjiyografik iğneler, kılıflar, kılavuz teller ve güvenlik ürünleri; anjiyografi, drenaj, dağıtım sistemleri ve emboloterapi ürünlerinden oluşan periferik müdahale ürünleri; yumuşak doku biyopsi ürünleri ve aksesuarları gibi onkoloji ürünleri sunmaktadır; kardiyak erişim, anjiyografi, elektrofizyoloji ve kardiyak ritim yönetimi, sıvı yönetimi, hemodinamik izleme, hemostaz ve müdahale ürünlerinden oluşan kardiyak müdahale ürünleri; ve vertebral ogmentasyon, radyofrekans ablasyon ve kemik biyopsi sistemlerini içeren omurga ürünleri.
Merit Medical Systems, Inc. Temel Bilgiler Özeti
| MMSI temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$5.42b |
| Kazançlar(TTM) | US$145.56m |
| Gelir(TTM) | US$1.58b |
MMSI aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MMSI gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.58b |
| Gelir Maliyeti | US$797.09m |
| Brüt Kâr | US$781.73m |
| Diğer Giderler | US$636.17m |
| Kazançlar | US$145.56m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 2.44 |
| Brüt Marj | 49.51% |
| Net Kâr Marjı | 9.22% |
| Borç/Özkaynak Oranı | 43.8% |
MMSI uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/17 11:45 |
| Gün Sonu Hisse Fiyatı | 2026/08/14 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Merit Medical Systems, Inc. 22 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Baird |
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |